Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of CX1440 in adults with chronic primary immune thrombocytopenia
CTR20253385Phase 3Active
- Sponsor
- Hangzhou Bangshun Pharmaceutical
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bangsaitinib in immune thrombocytopenia (ITP), sponsored by Hangzhou Bangshun Pharmaceutical. Started Nov 2025; status: active.
02
Drugs
bangsaitinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20253385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253385.